Genomics Startups

BillionToOne is a precision diagnostics company that uses molecular counting technology to develop non-invasive prenatal screening and liquid biopsy tests for early disease detection. The company focuses on making molecular diagnostics accurate, fast, and accessible to patients.

21 investors

Helix Nanotechnologies develops mRNA-based therapeutics for disease treatment and environmental applications, currently advancing a COVID-19 vaccine candidate for immunocompromised patients and testing interventions targeting climate challenges.

13 investors

Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models. The company aims to address the global shortage of liver transplants by developing new treatment options for liver fibrosis and cirrhosis.

10 investors

Genomelink develops a platform that provides individuals with access to and management of their genomic data, leveraging advances in DNA sequencing technology. The company serves consumers seeking personal genetic information and operates in the genomics and digital health sector.

9 investors

Kernal Bio is a synthetic biology company developing selective mRNA drugs to treat serious illnesses, with a focus on cancer therapeutics and improving patient outcomes.

7 investors

Probably Genetic operates a platform for diagnosing genetic diseases, providing comprehensive genetic data and testing to patients and healthcare providers. The company works with patient advocacy groups to connect patients with genetic conditions to diagnostic services and community support.

7 investors

54Gene conducts genomics research and provides related services to increase the representation of African genetic data in medical research, which aims to advance healthcare solutions globally.

6 investors

Nest Genomics develops genomics solutions to integrate genetic testing into routine patient care. The company is led by former Clear Genetics founders and employs genetic counselors and engineers.

6 investors

Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

6 investors

Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.

5 investors

CCG.ai develops software that uses clinical and genomic data to help oncologists select appropriate cancer treatments for individual patients, with a focus on identifying predictive biomarkers linked to treatment response.

4 investors

Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.

3 investors

Mable is a genomics-based telehealth platform that provides personalized migraine care by analyzing patients' genetic and biomarker data to inform individualized treatment plans. The company serves migraine sufferers seeking precision medicine alternatives to traditional trial-and-error medication approaches.

3 investors

One Codex provides microbiome sequencing data analysis and reporting software for academic labs, biotechnology companies, and clinical laboratories. The platform uses advanced algorithms and a curated database to analyze metagenomic samples with a web-based interface accessible to both bench scientists and computational biologists.

3 investors

Sequence Bio discovers genetic causes of disease within Newfoundland and Labrador's founder population to develop breakthrough treatments, diagnostics, and preventions. The company focuses on translational biology and genetics research for patients globally.

3 investors

Volta develops a hardware and software platform for genomics sample preparation that automates the extraction of biological information. The company serves researchers, laboratories, and healthcare organizations working in genomics, disease control, forensic science, and medicine.

3 investors

Anto is an AI research lab developing foundation models for microbial communities to enable precision medicine by computationally modeling how the microbiome affects individual drug response. The company serves pharmaceutical and clinical research by combining AI with genomic and microbiome data.

2 investors

Kern Systems develops a cold data storage platform using synthetic DNA molecules and enzymes to archive data with superior density, durability, and energy efficiency compared to traditional storage technologies. The platform targets the growing market for long-term archival storage of rarely-accessed unstructured data.

2 investors

Sigma Genetics makes devices that use magnetic fields to introduce DNA, RNA, and other charged molecules into cells, offering advantages over electroporation including reduced arcing, better scalability, and reduced invasiveness for in vivo applications. The technology targets cell therapies, cancer drug delivery, DNA vaccines, biopharmaceutical manufacturing, and cosmetics.

2 investors

Spiral Genetics develops software for analyzing and comparing whole human genome data across large populations to identify genetic patterns and variants. The company serves genetics testing firms, government agencies, and pharmaceutical companies seeking to discover new disease diagnostics and drug targets.

2 investors

XGenomes develops genomic sequencing technology using fluorescent probes and machine learning to read genetic and epigenetic information at single-molecule resolution. The platform enables frequent, rapid, and low-cost screening for healthcare providers and patients to support early disease detection and personalized preventive medicine.

2 investors

Circumvent develops precision medicines for neurodegenerative diseases, with current focus on Batten Disease and other rare neurological disorders. The company's research targets synaptic dysfunction and lysosomal pathways through investigation of the palmitoylome.

1 investor

Coral Genomics develops laboratory tests that combine molecular, functional, and clinical data to guide treatment selection for patients with autoimmune diseases, including those resistant to existing therapies.

1 investor

Dropprint Genomics develops software for analyzing individual cell activity in genomic data, serving researchers in immunology and drug discovery. The company reduces the cost and computational complexity of single-cell sequencing and maintains a database of over 1 million immune cells to support target identification using machine learning models.

1 investor